Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors

BACKGROUND. Immune‐checkpoint inhibitors (ICIs) are now standard of care for advanced non‐small cell lung cancer (NSCLC). Unfortunately, many patients experience immune‐related adverse events (irAEs), which are usually mild and reversible, but they require timely management and may be life threateni...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Pavan, Alberto, Calvetti, Lorenzo, Dal Maso, Alessandro, Attili, Ilaria, Del Bianco, Paola, Pasello, Giulia, Guarneri, Valentina, Aprile, Giuseppe, Conte, PierFranco, Bonanno, Laura
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Lung Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693718/
https://ncbi.nlm.nih.gov/pubmed/31015312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0563
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars